Comparison of the Effects of Epidural Analgesia and Local Infiltrative Analgesia Methods on Pain Control

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

51 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-05-01

Study Completion Date

2017-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Total knee arthroplasty (TKA) is one of the major orthopedic surgeries that cause severe postoperative pain. 60% of the patients undergoing TKA have severe pain and 30% have moderate pain postoperatively. Many methods are used in the effective treatment of pain after TKA. The administration of analgesic drugs to the wound site in the form of local infiltration is included in the pain treatment both as an independent technique and in addition to multimodal analgesia in the treatment of postoperative pain. Epidural analgesia (EA) is known for its place in the treatment of pain after TKA and its suppressive effect on the stress response. Similar to the study, no publication was found in the literature that evaluated the suppression of surgical stress response and the effectiveness of local infiltrative analgesia (LIA) in lower extremity surgery. Therefore, it was aimed in the study to compare the effects of EA and LIA on postoperative pain and stress response in patients who underwent total knee arthroplasty.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of Epidural Analgesia With Intra-Articular Infiltration Analgesia

NCT06872528

Epidural; Analgesia Local Infiltration

NOT_YET_RECRUITING NA

Efficacy of Peripheral Nerve Blocks in Total Knee Arthroplasty

NCT07040709

Postoperative Pain Following Knee Arthroplasty

RECRUITING NA

Femoral and Epidural Block After Total Knee Arthroplasty

NCT02115945

Acute Postoperative Pain Chronic Postoperative Pain

COMPLETED EARLY_PHASE1

Epidural Analgesia vs Adductor Canal Block in Bilateral TKA

NCT03205540

Osteo Arthritis Knee

COMPLETED NA

Comparison of Two Different Regional Anesthetic Methods in Total Knee Arthroplasty Patients

NCT07092982

Total Knee Arthroplasty Ultrasound Guided Supra-inguinal Fascia Iliaca Block Adductor Canal Block

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study was planned as a prospective, randomized and single-center study, and the study was started after the approval of the local ethics committee. Informed consent form was obtained from each participants. All surgeries were performed before 11 am to ensure that the measurements of endocrine parameters matched the diurnal rhythm.

A total of 51 ASA I-III participants scheduled for TKA were randomly divided into two groups using the closed envelope method. Groups were group E administered epidural analgesia (n=25) and group I local infiltrative analgesia (n=26). After an overnight fasting period, the participants who were taken to the operating room were hydrated with 500 mL of saline 30 minutes before the operation, and no premedication was applied to the patients. When the participants were taken to the operating table, routine ECG (DII), non-invasive blood pressure, and peripheral oxygen saturation were monitored.

The same surgical technique was performed by the same surgeon in both groups. The same prosthesis was used in both groups, 750 mg cefuroxime iv. for prophylactic antibiotics (Cefax; Vem Pharmaceutical Industry and Trade Ltd.) and the patients were administered diclofenac sodium 75 mg regularly every 12 hours (Diclomec; Abdi İbrahim Pharmaceuticals Ind. and Trade Inc.).

Group E: Participants in this group were entered the epidural space from the midline using the loss of resistance method with an 18-Gauge Touhy (Egemen Combifix Standard Spinal Epidural Combined Set; Braun) needle from the L4-L5 or L5-S1 vertebral space. After the free cerebrospinal fluid flow is observed by passing the spinal needle through the epidural needle, spinal anaesthesia was maintained with 10-15 mg hyperbaric bupivacaine (Bustesin 0.5% Spinal Heavy; Vem Pharmaceuticals Industry and Trade Ltd.). After the epidural catheter was fixed in such a way that it remained 5 cm in the epidural space, the adapter was inserted and fixed. Whether the catheter is in place or not was checked by 2 mL (40 mg) Lidocaine (Aritmal; Osel Pharmaceuticals Ind. Inc.) + 1/2000000 adrenaline test dose. At the end of the surgery, when the Bromage score is 2 in the recovery room, 60 mL 0.9% NaCl + 0.5% 60 mL bupivacaine (Marcaine 0.5%; AstraZeneca Industry and Trade Ltd.) was inserted into the epidural catheter to provide continuous infusion at a rate of 5 mL/hour, and the participants were followed in the postanesthetic care unit for 24 hours.

Group I: In this group, spinal anesthesia was maintained with 10-15 mg of hyperbaric bupivacaine (Bustesin 0.5% Spinal Heavy; Vem Pharmaceutical Industry and Trade Ltd.) after free cerebrospinal fluid flow was observed by entering the subarachnoid space with a 22 G spinal needle (Egemen Quincke Sharpened Spinal Anesthesia Needle; İzmir) from the L4-L5 or L5-S1 vertebral space. At the end of the operation, a 20-gauge infiltrative analgesia catheter connected to an ON-Q elastomeric pump that provides 5 mL/hour infusion prepared with 60 mL of 0.9% NaCl + 60 mL of 0.5% Bupivacaine (Marcaine 0.5%; AstraZeneca Industry and Trade Ltd.) was placed on the fascia by the surgeon in such a way that all the holes of the catheter were under the skin and parallel to the incision line. When the Bromage score was 2 in the postoperative recovery room, drug infusion was started with an incisional pain pump and the catheter was withdrawn at the end of the postoperative 24th hour.

Bromage score used in participants in the epidural analgesia group; 0: No paralysis, the patient can move his foot and knee fully; 1: The patient only moves his knee and foot, cannot raise his leg straight; 2: The patient cannot move the knee, only the ankle; 3: It was evaluated as complete paralysis.

In the postoperative period in participants 4th, 6th, 12th, pain at rest and with movement (passive flexion movement to the knee joint at the operation site) was measured with the Visual Analog Scale (VAS) at the 24th. VAS assessment was done by asking the participants to mark a point on a 10 cm horizontal line that shows (initial "no pain", end "unbearable pain") the start and end points and is equivalent to the pain on this line. In both groups, if the VAS value is 4 and above, 50 mg iv. tramadol hydrochloride (Contromal; Abdi İbrahim Pharmaceuticals Ind. and Trade Inc.) additional dose was administered.

Tramadol hydrochloride consumption and side effects were evaluated as nausea (0=absent, 1=mild, 2=severe) and vomiting (0=absent, 1=mild, 2=severe). The presence of urinary retention and abdominal distension was recorded. Venous blood samples were taken in the preoperative period, at the 1st hour, 4th hour, and 24th hour postoperatively to evaluate the stress response.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Epidural Anesthesia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Epidural

Patients in this group were entered the epidural space from the midline using the loss of resistance method with an 18-Gauge Touhy (Egemen®, Combifix Standard Spinal Epidural Combined Set, İzmir, Turkey) needle from the L4-L5 or L5-S1 vertebral space.

Group Type ACTIVE_COMPARATOR

18-Gauge Touhy (Egemen®, Combifix Standard Spinal Epidural Combined Set, İzmir, Turkey)

Intervention Type DEVICE

Patients in this group were entered the epidural space from the midline using the loss of resistance method with an 18-Gauge Touhy (Egemen®, Combifix Standard Spinal Epidural Combined Set, İzmir, Turkey) needle from the L4-L5 or L5-S1 vertebral space. After the free cerebrospinal fluid flow is observed by passing the spinal needle through the epidural needle, spinal anaesthesia was maintained with 10-15 mg hyperbaric bupivacaine (Bustesin®, 0.5% Spinal Heavy Vem Pharmaceuticals, Turkey). After the epidural catheter was fixed in such a way that it remained 5 cm in the epidural space, the adapter was inserted and fixed. Whether the catheter is in place or not was checked by 2 mL (40 mg) Lidocaine (Aritmal®, 2% 100 mg/5 mL amp., Biosel, Turkey) + 1/2000000 adrenaline test dose.

local infiltrative analgesia

At the end of the operation, a 20-gauge infiltrative analgesia catheter connected to an ON-Q elastomeric pump that provides 5 mL/hour infusion prepared with 60 mL of 0.9% NaCl + 60 mL of 0.5% Bupivacaine (Bustesin®, 0.5% Spinal Heavy Vem Pharmaceuticals, Turkey) was placed on the fascia by the surgeon in such a way that all the holes of the catheter were under the skin and parallel to the incision line.

Group Type ACTIVE_COMPARATOR

20-gauge infiltrative analgesia catheter connected to an ON-Q elastomeric pump

Intervention Type DEVICE

spinal anesthesia was maintained with 10-15 mg of hyperbaric bupivacaine (Bustesin 0.5% Spinal Heavy; Vem Pharmaceutical Industry and Trade Ltd.) after free cerebrospinal fluid flow was observed by entering the subarachnoid space with a 22 G spinal needle (Egemen Quincke Sharpened Spinal Anesthesia Needle; İzmir) from the L4-L5 or L5-S1 vertebral space. At the end of the operation, a 20-gauge infiltrative analgesia catheter connected to an ON-Q elastomeric pump that provides 5 mL/hour infusion prepared with 60 mL of 0.9% NaCl + 60 mL of 0.5% Bupivacaine (Marcaine 0.5%; AstraZeneca Industry and Trade Ltd.) was placed on the fascia by the surgeon in such a way that all the holes of the catheter were under the skin and parallel to the incision line. Pain pump and the catheter was withdrawn at the end of the postoperative 24th hour.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

18-Gauge Touhy (Egemen®, Combifix Standard Spinal Epidural Combined Set, İzmir, Turkey)

Patients in this group were entered the epidural space from the midline using the loss of resistance method with an 18-Gauge Touhy (Egemen®, Combifix Standard Spinal Epidural Combined Set, İzmir, Turkey) needle from the L4-L5 or L5-S1 vertebral space. After the free cerebrospinal fluid flow is observed by passing the spinal needle through the epidural needle, spinal anaesthesia was maintained with 10-15 mg hyperbaric bupivacaine (Bustesin®, 0.5% Spinal Heavy Vem Pharmaceuticals, Turkey). After the epidural catheter was fixed in such a way that it remained 5 cm in the epidural space, the adapter was inserted and fixed. Whether the catheter is in place or not was checked by 2 mL (40 mg) Lidocaine (Aritmal®, 2% 100 mg/5 mL amp., Biosel, Turkey) + 1/2000000 adrenaline test dose.

Intervention Type DEVICE

20-gauge infiltrative analgesia catheter connected to an ON-Q elastomeric pump

spinal anesthesia was maintained with 10-15 mg of hyperbaric bupivacaine (Bustesin 0.5% Spinal Heavy; Vem Pharmaceutical Industry and Trade Ltd.) after free cerebrospinal fluid flow was observed by entering the subarachnoid space with a 22 G spinal needle (Egemen Quincke Sharpened Spinal Anesthesia Needle; İzmir) from the L4-L5 or L5-S1 vertebral space. At the end of the operation, a 20-gauge infiltrative analgesia catheter connected to an ON-Q elastomeric pump that provides 5 mL/hour infusion prepared with 60 mL of 0.9% NaCl + 60 mL of 0.5% Bupivacaine (Marcaine 0.5%; AstraZeneca Industry and Trade Ltd.) was placed on the fascia by the surgeon in such a way that all the holes of the catheter were under the skin and parallel to the incision line. Pain pump and the catheter was withdrawn at the end of the postoperative 24th hour.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ASA II and III,
* Aged between 18-80 years,
* who were scheduled to undergo unilateral knee arthroplasty,
* who giving consent.

Exclusion Criteria

* who will undergo an extra surgical procedure or who will undergo bilateral knee arthroplasty,
* those with local anaesthetic sensitivity,
* morbidly obese,
* those with additional pathology that may constitute a contraindication to the application of regional anaesthesia,
* those who did not give voluntary consent,
* had a history of anticoagulant drug use,
* had a history of cerebrovascular disease,
* who received steroid therapy for any disease, were diabetic,
* had a homeostasis assessment score (HOMA) above 2.5.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes